Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cancer therapies and diagnostics group Avacta said it had entered into a license agreement with Biokit, a Werfen company, to incorporate its affimer reagents into a Biokit in-vitro diagnostic product.
'The license agreement follows an extensive evaluation by Biokit of certain Affimer reagents to detect a key analyte,' the company said.
Under the terms of the agreement, Biokit had the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners a diagnostic immunoassay for this analyte.
Avacta would receive royalties on future sales of any products brought to market following completion of product development and regulatory approvals.
At 9:55am: (LON:AVCT) Avacta Group PLC share price was 0p at 111.5p